KREBSDIAGNOSTIK MIT NICHTCODIERENDEN TRANSKRIPTEN

European patent · EP2791359 · In force

Register entry

Publication number
EP2791359
Application number
EP12857492
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 13, 2012
Published
Oct 22, 2014
Granted
Jan 15, 2020
Protection ends at the latest
Dec 12, 2032
Next annual fee due
Dec 31, 2026
IPC classes
C12Q 1/68 (2018.01)
C12M 1/34 (2006.01)
G01N 33/574 (2006.01)
C12N 15/11 (2006.01)
Priority
US 201161570194 P 13.12.2011
US 201261652044 P 25.05.2012
US 201261730426 P 27.11.2012
PCT application
PCT/US2012/069571 13.12.2012
PCT publication
WO2013/090620 20.06.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Oct 20, 2023

    Transferred

    Owner
    Decipher Biosciences, Inc., 10355 Science Center Drive, Suite 240, San Diego, CA 92121, USA → Veracyte, Inc., Suite 300, 6000 Shoreline Ct, South San Francisco, CA 94080, USA
    Representative
    BOVARD AG, Patent- und Markenanwälte, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 20.10.2023

  5. Jan 1, 2023

    Change

    Published in Swissreg on 01.01.2023

  6. Jan 15, 2020

    Granted

    Published in Swissreg on 15.01.2020

Parties

Inventor

VERGARA CORREA, Ismael, A.

West Vancouver, British Columbia V7W 1C3, CA

DAVICIONI, Elai

La Jolla, CA 92037, US

ERHO, Nicholas, George

Vancouver, Bristish Columbia V6H 1Y2, CA

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.